This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (28)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Otolaryngology/ Head & Neck Surgery  • Surgical Oncology  • Endocrine Diseases  • Thyroid/ Parathyroid Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Electron Kebebew, MD; Shoichi Kikuchi, MD, PhD; Quan-Yang Duh, MD; Orlo H. Clark, MD

Arch Surg. 2000;135:895-901.

Hypothesis  Reoperation benefits patients with locoregional, persistent, or recurrent medullary thyroid cancer (MTC). Currently available localizing studies have limited utility for detecting all foci of residual MTC.

Design  A retrospective study with a mean follow-up time of 7.5 years (median, 13 years; range, 2.2-29 years).

Setting  A tertiary referral medical center.

Patients  Thirty-three patients who underwent 46 reoperations for locoregional residual MTC.

Results  Sixty-four percent of residual MTC was located in the lateral cervical nodes, 22% in the central cervical nodes or thyroid bed, and 14% in the anterior mediastinum (197 of 1128 nodes resected were positive for MTC). After reoperation, basal calcitonin levels were undetectable in 2 patients, reduced by greater than 50% in 10 patients, and either increased or were not reduced by greater than 50% in the remaining patients. On reoperation, one patient had a thoracic duct injury that required reexploration and ligation. Patients who had a greater than 50% decrease in calcitonin levels after reoperation were less likely to develop distant metastases compared with patients who did not have a greater than 50% decrease (P<.05). The sensitivities of magnetic resonance imaging (n = 31), computed tomographic scan (n = 16), ultrasound (n = 9), and dimercaptosuccinic acid scan (n = 3) were 91%, 86%, 88%, and 100%, respectively.

Conclusions  Although reoperation in patients with residual MTC rarely results in biochemical cure, cervical reexploration is safe and in selected patients may limit MTC progression. Lateral cervical node dissection could be beneficial at the time of initial surgical treatment because of the high frequency of residual MTC in the lateral cervical nodes. Noninvasive imaging studies were helpful but far from perfect for guiding the reexploration for locoregional residual MTC.

From the Department of Surgery, University of California–San Francisco and Mount Zion Medical Center, San Francisco (Drs Kebebew, Kikuchi, and Clark), and Surgical Services, Veterans Affairs Medical Center, San Francisco (Dr Duh).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

18F-Dihydroxyphenylalanine PET in Patients with Biochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation
Koopmans et al.
JNM 2008;49:524-531.
ABSTRACT | FULL TEXT  

Expression and role of estrogen receptor {alpha} and {beta} in medullary thyroid carcinoma: different roles in cancer growth and apoptosis
Cho et al.
J Endocrinol 2007;195:255-263.
ABSTRACT | FULL TEXT  

Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma
Barbet et al.
J. Clin. Endocrinol. Metab. 2005;90:6077-6084.
ABSTRACT | FULL TEXT  

The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors
Kaltsas et al.
Endocr. Rev. 2004;25:458-511.
ABSTRACT | FULL TEXT  

Skip Metastases in Thyroid Cancer Leaping the Central Lymph Node Compartment
Machens et al.
Arch Surg 2004;139:43-45.
ABSTRACT | FULL TEXT